Key result
IFN-alpha treatment in hepatitis C is linked to increased mononuclear NOS2 expression and decreased ALT.
Why the study?
Does Interferon-alpha increase NOS2 expression and NO production in human mononuclear cells in vitro and in patients with hepatitis C?
Observational
Does Interferon-alpha increase NOS2 expression and NO production in human mononuclear cells in vitro and in patients with hepatitis C?
IFN-alpha induces NOS2 expression and NO production in human mononuclear cells, which may contribute to its antiviral effects in hepatitis C.
IFN-alpha may act partly via NOS2 in hepatitis C; extends in vitro data but leaves open causal role and clinical utility.
Although researchers have noted high level activation of rodent mononuclear phagocytes for nitric oxide (NO) synthase type 2 (S2) expression and NO production with a variety of agents such as interferon (IFN) gamma and endotoxin, it has been difficult to demonstrate activation of human mononuclear phagocytes. The purpose of this study was to determine if IFN-alpha serves as an activator in vitro and in vivo in humans. Treatment of normal monocytes or mononuclear cells in vitro with IFN-alpha caused a dose-dependent increase in monocyte NOS2 activity and NO production, and increased expression of NOS2 protein and mRNA expression. To determine if in vivo administration of IFN-alpha also modulated NOS2, we studied blood cells from patients with hepatitis C before and after IFN-alpha therapy. Untreated patients with chronic hepatitis C virus infection had levels of NOS activity and NOS2 antigen in freshly isolated mononuclear cells similar to those of healthy subjects, and they expressed minimal or no NOS2 mRNA. However, IFN-alpha treatment of patients with hepatitis C infection was associated with a significant elevation in mononuclear cell NOS activity, NOS2 antigen content, and NOS2 mRNA content. IFN-alpha-treated patients had significant decreases in levels of serum alanine aminotransferase and plasma hepatitis C mRNA. The degree of IFN-alpha-enhanced mononuclear cell NOS2 antigen content correlated significantly with the degree of reduction in serum alanine aminotransferase levels. Thus, IFN-alpha treatment of cells in vitro or administration of IFN-alpha to hepatitis C patients in vivo increases expression of mononuclear cell NOS2 mRNA expression, NOS activity, NOS2 antigen expression, and NO production. Since NO has been reported to have antiviral activity for a variety of viruses, we speculate that induced NO production may be related to the antiviral action(s) of IFN-alpha in hepatitis C infection.
No takes yet. Share an insight, caveat, or question.
Sharara et al. (1997) conducted an observational in Hepatitis C. IFN-alpha vs. Baseline (untreated) and healthy subjects was evaluated on Mononuclear cell NOS activity, NOS2 antigen content, and NOS2 mRNA content. IFN-alpha treatment in patients with hepatitis C significantly increased mononuclear cell NOS2 expression, which correlated with decreased serum alanine aminotransferase levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: